⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4247378 | 1.00 | — | — | |
| SCHEMBL8917932 | 1.00 | — | — | |
| SCHEMBL18341554 | 0.76 | — | — | |
| SCHEMBL14890206 | 0.76 | — | — | |
| SCHEMBL727656 | 0.76 | — | — | |
| SCHEMBL1320186 | 0.74 | — | — | |
| SCHEMBL24939564 | 0.73 | — | — | |
| SCHEMBL888890 | 0.73 | — | — | |
| SCHEMBL9538317 | 0.73 | — | — | |
| SCHEMBL22334216 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820756-B2 | Bradykinin B2 receptor antagonists | Pharvaris Netherlands B.V. (NL) | 2023-11-21 | — | — | US | disclosed |
| US-20230128198-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230128198-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-04-27 | — | — | US | disclosed |
| US-11384066-B1 | Heterocyclic compounds useful as aurora a selective inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-07-12 | — | — | US | disclosed |
| US-20200255405-A1 | NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS | ANALYTICON DISCOVERY GMBH (DE) | 2020-08-13 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-8314135-B2 | Linked dibenzimidazole antivirals | ENANTA PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-8030354-B2 | 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes | AMGEN INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20110190330-A1 | SPIROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110008288-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-01-13 | — | — | US | disclosed |
| US-20100298367-A1 | Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders | AMGEN INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100266543-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-05-28 | — | — | US | disclosed |